Search results
Showing 211 to 225 of 442 results for cardiovascular disease
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
What is the effectivness of statin treatment in older people?
Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)
Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.
View recommendations for HTG213Show all sections
Sections for HTG213
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.
monitoring treatment and blood pressure targets for people without cardiovascular disease. Full details of the evidence and the...
the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...
the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...
. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
diabetes. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid...
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....